NHS Cervical Screening Programme: Overview
change effective 1 July 2025
This is programme-operational guidance (who is invited, when, and how the pathway works) — distinct from clinical management of an abnormal result, which is covered in NICE and RCOG guidance on colposcopy referral and cervical pathology.
Who Is Screened
- Women and people with a cervix aged 25-64 in England.
- First invitation sent at age 24.5.
- Overseas visitors: eligibility follows NHS overseas visitor charging regulations, clarified in programme updates through 2026.
Screening Interval
- Uniform 5-yearly interval for ages 25-64, effective 1 July 2025. This replaced the previous split interval (3-yearly for 25-49, 5-yearly for 50-64).
- The change was possible because HPV primary testing is substantially more sensitive than the cytology-first approach it replaced in 2019 — a negative HPV test carries a very low risk of missed high-grade disease over 5 years, at any age in the screened range.
- HPV-vaccinated individuals must still attend screening — current vaccines do not cover every oncogenic HPV subtype.
HPV Primary Screening Pathway
- HPV test first on the sample (not cytology first, which was the pre-2019 approach).
- HPV negative → routine recall in 5 years.
- HPV positive → reflex cytology triage is performed on the same
sample:
- Cytology abnormal → refer to colposcopy.
- Cytology normal → repeat HPV test in 12 months ("test of cure" / surveillance pathway); persistent HPV positivity with normal cytology over repeated rounds leads to colposcopy referral.
High-Yield Exam Points
- Know that the interval is now uniform 5-yearly across the whole 25-64 range, not the older 3/5-year split — this is a recent change (1 July 2025) and a common place for stale information to persist in older revision material.
- HPV-first testing, not cytology-first, is the current primary screening method — cytology is now a triage step after a positive HPV result, not the initial test.
- This is programme/pathway knowledge, distinct from the clinical
pathology of CIN grading and cervical cancer staging (see
pathology-gynaecological.md).
Source: NHS England / gov.uk cervical screening programme guidance (Programme pages updated through 2025-2026; interval)
MRCOG AI is an independent educational tool. It is not affiliated with, endorsed by, or connected to the Royal College of Obstetricians and Gynaecologists (RCOG).